Skip to main content

Peer Review reports

From: Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial

Original Submission
2 Aug 2017 Submitted Original manuscript
7 Sep 2017 Reviewed Reviewer Report - Kathy Gately
19 Dec 2017 Reviewed Reviewer Report - Roberto Passera
30 Jan 2018 Author responded Author comments - Zsolt Markoczy
Resubmission - Version 2
30 Jan 2018 Submitted Manuscript version 2
5 Feb 2018 Reviewed Reviewer Report - Roberto Passera
6 Feb 2018 Reviewed Reviewer Report - Kathy Gately
8 Mar 2018 Author responded Author comments - Zsolt Markoczy
Resubmission - Version 3
8 Mar 2018 Submitted Manuscript version 3
12 Mar 2018 Reviewed Reviewer Report - Roberto Passera
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
21 Mar 2018 Editorially accepted
25 May 2018 Article published 10.1186/s12885-018-4283-z

You can find further information about peer review here.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us